Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Curcumin supplement study for memory fails to launch

NCT ID NCT07251985

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a daily curcumin supplement could improve memory and attention in adults aged 50 to 85 with age-related memory complaints. Participants would have taken curcumin or a placebo for up to 12 months. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
curcumin (Theracurmin Super TS-P1)
What this could lead to
If it had succeeded, this could point toward a dietary supplement that helps slow age-related memory decline.
What could go wrong
The study was withdrawn before enrolling anyone, so no results are available. Even if conducted, earlier evidence was based on a very small sample, and supplements often fail to show clear benefits in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Started

Apr 2026

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Presence of age-related memory complaints; 2. Male or female aged 50 to 85 years of age at Visit 1. 3. performance on MoCA test of \>= 18 (Milani et al, 2018) 4. Ability to perform normal daily activities independently (which excludes a diagnosis of dementia). 5. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. 6. Agreement to participate in the entire study, which could last either 6 or 12 months depending on results of the interim analysis. 7. Adequate visual and auditory acuity for cognitive testing. 8. Screening laboratory tests that do not show significant medical problems that might interfere with study participation or impact cognitive test results. 9. Psychotropic medication, if used, should be stable for at least 2 weeks prior to randomization. 10. Agreement to avoid taking any curcumin, turmeric supplements or cognitive enhancing medicines or supplements during the course of the study. Exclusion Criteria 1. Allergy to curcumin 2. Presence of a condition or abnormality that in the opinion of the site Principal Investigator would compromise the safety of the patient or the quality of the data. 3. Significant cerebrovascular disease or Alzheimer disease or any other dementia. 4. Neurological or physical illnesses that can produce cognitive deterioration. 5. History of myocardial infarction within the previous year or unstable cardiac disease. 6. Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100); significant liver or pulmonary disease, or cancer; 7. Current diagnosis of any major psychiatric disorder according to the DSM-IV TR criteria with a change in medication or clinical symptoms with the last 3 months prior to screening (APA, 2000). 8. History of alcoholism or substance addiction in the last 15 years. 9. Current treatment for seizure disorder; 10. Abnormal laboratory values with clinical significance in the opinion of the site Principal Investigator. 11. Current unstable medical illness including delirium, worsening congestive heart failure, unstable angina, recent myocardial infarctions, acute infectious disease, severe renal or hepatic failure, severe respiratory disease, metastatic cancer, or other conditions that, in the Principal Investigator's opinion, could interfere with the analysis of safety and efficacy in this study. 12. A 2-week washout is required prior to baseline for any of the following: curcumin or turmeric supplements, any anti-inflammatory medication other than occasional use (e.g., once per week). 13. The subject may not be an immediate family member (e.g., spouse, parent, child, sibling) of personnel directly affiliated with this study, the study site or study funding agency.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive function decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.